Clinical Trial Update: DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant [Phase 4]

View source ↗

Summary

Phase 4 trial update on direct-acting antiviral (DAA) treatment for donor HCV-positive to recipient HCV-negative heart transplant; the study is terminated with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Heart Disease
• Hepatitis C

Snippet

Sponsor: Massachusetts General Hospital | Conditions: End Stage Heart Disease, Hepatitis C | Phase 4 | Status: TERMINATED | Results posted: 2022-06-02